EUVIMEDEUVIMED entdecken
Crossref

Modeling the Structure of Ketoprofen-Poly(vinylpyrrolidone) Amorphous Solid Dispersions with Empirical Potential Structure Refinements of X-ray Scattering Data

Stephen K Wilke iD, Abdulrahman Al-Rubkhi, Chris J Benmore, Stephen R Byrn, Richard Weber

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Stephen K Wilke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Materials Development, Inc., Arlington Heights, Illinois 60004, United States. Hauptthemen laut MEDLINE: Ketoprofen, Povidone, X-Ray Diffraction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The metastability of amorphous formulations poses barriers to their safe and widespread commercialization. The propensity of amorphous solid dispersions (ASDs) to crystallize is directly linked to their molecular structure. Amorphous structures are inherently complex and thus difficult to fully characterize by experiments, which makes structural simulations an attractive route for investigating which structural characteristics correlate with ASD stability. In this study, we use empirical potential structure refinement (EPSR) to create molecular models of ketoprofen-poly(vinylpyrrolidone) (KTP/PVP) ASDs with 0-75 wt % drug loading. The EPSR technique uses X-ray total scattering measurements as constraints, yielding models that are consistent with the X-ray data. We perform several simulations to assess the sensitivity of the EPSR approach to input parameters such as intramolecular bond rotations, PVP molecule length, and PVP tacticity. Even at low drug loading (25 wt %), ∼40% of KTP molecules participate in KTP-KTP hydrogen bonding. The extent of KTP-PVP hydrogen bonding does not decrease significantly at higher drug loadings. However, the models' relative uncertainties are too large to conclude whether ASDs' lower stabilities at high drug loadings are due to changes in drug-excipient hydrogen bonding or a decrease in steric hindrance of KTP molecules. This study illustrates how EPSR, combined with total scattering measurements, can be a powerful tool for investigating structural characteristics in amorphous formulations and developing ASDs with improved stability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetoprofenPovidoneX-Ray DiffractionCrystallizationChemistry, PharmaceuticalDrug CompoundingModels, MolecularDrug Stability

Stichwörter der Autor:innen

EPSR modelingKollidonX-ray diffractionamorphous solid dispersionketoprofenmolecular structurepoly(vinylpyrrolidone)

Substanzen

KetoprofenPovidone

Autor:innen und Institutionen

  • Materials Development, Inc., Arlington Heights, Illinois 60004, United States.
  • X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois 60439, United States.
  • Improved Pharma, West Lafayette, Indiana 47906, United States.

ORCID-Profile: Stephen K Wilke

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Wilke, S. K., Al-Rubkhi, A., Benmore, C. J., Byrn, S. R., & Weber, R. (2024). Modeling the Structure of Ketoprofen-Poly(vinylpyrrolidone) Amorphous Solid Dispersions with Empirical Potential Structure Refinements of X-ray Scattering Data. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00313

Vancouver

Wilke SK, Al-Rubkhi A, Benmore CJ, Byrn SR, Weber R. Modeling the Structure of Ketoprofen-Poly(vinylpyrrolidone) Amorphous Solid Dispersions with Empirical Potential Structure Refinements of X-ray Scattering Data. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00313

BibTeX
@article{Wilke2024,
  author = {Wilke, Stephen K and Al-Rubkhi, Abdulrahman and Benmore, Chris J and Byrn, Stephen R and Weber, Richard},
  title = {Modeling the Structure of Ketoprofen-Poly(vinylpyrrolidone) Amorphous Solid Dispersions with Empirical Potential Structure Refinements of X-ray Scattering Data},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00313}
}
Kostenlos starten →